美国吉利德科学公司近日公布了2期临床研究EVOKE-02的初步数据结果:ADC药物Trodelvy与PD-1药物Keytruda联用,一线治疗晚期或转移性非小细胞肺癌展现出了积极疗效。 EVOKE-02研究详情 EVOKE-02研究是一项在全球范围内开展的多中心、开放标签、多队列...
EVOKE-02研究是一项全球、开放性、多队列Ⅱ期研究,评估戈沙妥珠单抗+帕博利珠单抗±铂类在无可靶向基因改变的转移性NSCLC初治患者的疗效和安全性。本次WCLC会上将会报告队列A和队列B接受SG+帕博利珠单抗治疗的初步结果。 EVOKE-02研究选...
Jhanelle E. Gray | Sacituzumab Govitecan + Pembrolizumab + Carboplatin in 1L Metastatic Non-Small Cell Lung Cancer: The EVOKE-02 Study aAssessed by investigator per RECIST v1.1 bSG IV until progressive disease or unacceptable toxicity. cPembro IV up to 35 cycles. dCarboplatin up to 4 cycles...
She notes the EVOKE-01 second-line trial data will also help characterize the utility of this ADC. In summary, the early stage EVOKE-02 data shows the feasibility of combining the ADC sacituzumab govitecan with pembrolizumab as first-line treatment for NSCLC, but whether efficacy will prove s...
陆舜教授:EVOKE-02研究是一项全球、开放性、多队列Ⅱ期研究,旨在评估戈沙妥珠单抗+帕博利珠单抗±铂类在无可靶向基因改变的转移性NSCLC初治患者的疗效和安全性。该研究设计了4个队列:队列A为PD-L1肿瘤比例评分(TPS)≥50%的鳞癌或非鳞癌患者,队列B为PD-L1 TPS<50%的鳞癌或非鳞癌患者,此两组患者予以SG(10 mg...
免疫治疗药物以及ADC药物在NSCLC领域快速发展,成为了近期研究的热点。 PD-1/PD-L1单抗是一线转移性NSCLC(mNSCLC)患者的标准治疗方案,具有良好的疗效;戈沙妥珠单抗(SG)是一种Trop-2靶向ADC药物,在既往接受过治疗的mNSCLC患者中表现出较好临床活性且安全性可控,这两种药物协同的新型联合治疗模式是否能够进一步改善患者结...
Cho BC, Cobo Dols M, Reyes Cabanillas R, et al. Sacituzumab Govitecan + Pembrolizumab in 1L Metastatic Non–Small Cell Lung Cancer: Preliminary Results of the EVOKE-02 Study. Abstract presented at: World Conference on Lung Cancer, September 9-12, 2023...
Sacituzumab govitecan (SG) + pembrolizumab (pembro) in first-line (1L) metastatic non-small cell lung cancer (mNSCLC) with PD-L1 ≥ 50%: Cohort A of EVOKE-02. Sacituzumab govitecan (SG) + pembrolizumab (pembro) in first-line (1L) metastatic non-small cell lung cancer (mNSCLC) with...
EVOKE-02 (NCT05186974) is an open-label, multicohort phase II study evaluating SG + pembro± a platinum agent in 1L mNSCLC. Here we report results by histology (squamous vs nonsquamous) in patients treated with SG + pembro in Cohorts A and B of EVOKE-02. Methods Patients aged ≥ 18 ...
推荐理由:戈沙妥珠单抗用于二线非小细胞肺癌的III期注册性临床试验EVOKE-01研究未达到主要终点,相较于多西他赛组,戈沙妥珠单抗组患者总生存期的提高不具有统计学差异。戈沙妥珠单抗是全球首款获批的TROP2 ADC药物,此前已被获批用于乳腺癌与尿路上皮癌的治疗,但在非小细胞肺癌上的探索中遭遇失利,其后续研究值得关注...